2.9K(top 0.1%)
papers
65.4K(top 0.1%)
citations
101(top 0.1%)
h-index
207(top 0.1%)
g-index
3.2K
all documents
72.6K
doc citations
6.8K
citing journals

Top Articles

#TitleJournalYearCitations
1International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaLancet Oncology, The20143,343
2Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017JAMA Surgery20172,099
3International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaLancet Oncology, The20161,866
4AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung CancerNew England Journal of Medicine20151,802
5Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsNew England Journal of Medicine20141,645
6Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain MetastasesJAMA - Journal of the American Medical Association20161,225
7Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyLancet, The20201,224
8PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology20171,067
9Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive SarcomaJournal of Clinical Oncology2015778
10Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionJAMA - Journal of the American Medical Association2016759
11Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialLancet, The2016724
12ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver InjuryAmerican Journal of Gastroenterology2014631
13Guidelines for Perioperative Care in Cardiac SurgeryJAMA Surgery2019593
14Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyLancet Oncology, The2020544
15Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to OsimertinibJAMA Oncology2018522
16Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialLancet, The2016512
17Achieving desired results and improved outcomes: Integrating planning and assessment throughout learning activitiesJournal of Continuing Education in the Health Professions2009506
18Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJournal of Clinical Oncology2017470
19New Requirements for Resident Duty HoursJAMA - Journal of the American Medical Association2002453
20Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung CancerJAMA Oncology2020446
21Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialBlood2020436
22Guidelines for the management of hiatal herniaSurgical Endoscopy and Other Interventional Techniques2013404
23Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupLancet Oncology, The2017394
24Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyJournal of Clinical Oncology2017384
25International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman diseaseBlood2017381
26Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialLancet Oncology, The2017377
27Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementJournal of Clinical Oncology2017331
28Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus StatementJournal of Clinical Oncology2015330
29Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury NetworkHepatology2014326
30Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and RecommendationsBiology of Blood and Marrow Transplantation2014305
31Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 studyLancet, The2020299
32Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerJAMA Oncology2019285
332018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th Annual ReportClinical Toxicology2019284
34The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 1—Background, Design Considerations, and Model DevelopmentAnnals of Thoracic Surgery2018281
35Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialJournal of Clinical Oncology2019280
36The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 2—Statistical Methods and ResultsAnnals of Thoracic Surgery2018268
37Implementing TMB measurement in clinical practice: considerations on assay requirementsESMO Open2019257
382019 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 37th Annual ReportClinical Toxicology2020253
39B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approachesLeukemia2020253
40SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudyCancer Discovery2018244
41Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial InfarctionJournal of the American College of Cardiology2015240
42A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology CommitteeJournal of Thoracic Oncology2020234
43International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseBlood2018232
44Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial CancerJAMA Oncology2020229
45New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Leukemia2014214
46CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceFrontiers in Immunology2018212
47Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesBlood2017210
48The current state of molecular testing in the treatment of patients with solid tumors, 2019Ca-A Cancer Journal for Clinicians2019203
49Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac ScreeningJAMA Cardiology2021202
50A Mind-Body Program for Older Adults With Chronic Low Back PainJAMA Internal Medicine2016200